197 related articles for article (PubMed ID: 34110646)
1. A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer.
Abdulkareem NM; Bhat R; Qin L; Vasaikar S; Gopinathan A; Mitchell T; Shea MJ; Nanda S; Thangavel H; Zhang B; De Angelis C; Schiff R; Trivedi MV
FASEB J; 2021 Jul; 35(7):e21719. PubMed ID: 34110646
[TBL] [Abstract][Full Text] [Related]
2. GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.
Bhat RR; Yadav P; Sahay D; Bhargava DK; Creighton CJ; Yazdanfard S; Al-Rawi A; Yadav V; Qin L; Nanda S; Sethunath V; Fu X; De Angelis C; Narkar VA; Osborne CK; Schiff R; Trivedi MV
Breast Cancer Res Treat; 2018 Jul; 170(2):279-292. PubMed ID: 29574636
[TBL] [Abstract][Full Text] [Related]
3. NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer.
Bhat R; Thangavel H; Abdulkareem NM; Vasaikar S; De Angelis C; Bae L; Cataldo ML; Nanda S; Fu X; Zhang B; Schiff R; Trivedi MV
Sci Rep; 2022 Feb; 12(1):1972. PubMed ID: 35121782
[TBL] [Abstract][Full Text] [Related]
4. Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
Lyu C; Ye Y; Lensing MM; Wagner KU; Weigel RJ; Chen S
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34343132
[TBL] [Abstract][Full Text] [Related]
5. Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis.
Zhao H; Martin E; Matalkah F; Shah N; Ivanov A; Ruppert JM; Lockman PR; Agazie YM
Oncogene; 2019 Mar; 38(13):2275-2290. PubMed ID: 30467378
[TBL] [Abstract][Full Text] [Related]
6. circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer.
Ling Y; Liang G; Lin Q; Fang X; Luo Q; Cen Y; Mehrpour M; Hamai A; Liu Z; Shi Y; Li J; Lin W; Jia S; Yang W; Liu Q; Song E; Li J; Gong C
Mol Cancer; 2022 Jan; 21(1):8. PubMed ID: 34980129
[TBL] [Abstract][Full Text] [Related]
7. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
Zhang K; Hong R; Kaping L; Xu F; Xia W; Qin G; Zheng Q; Lu Q; Zhai Q; Shi Y; Yuan Z; Deng W; Chen M; Wang S
Cancer Lett; 2019 Apr; 447():130-140. PubMed ID: 30677445
[TBL] [Abstract][Full Text] [Related]
8. Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
Bashari MH; Fan F; Vallet S; Sattler M; Arn M; Luckner-Minden C; Schulze-Bergkamen H; Zörnig I; Marme F; Schneeweiss A; Cardone MH; Opferman JT; Jäger D; Podar K
Breast Cancer Res; 2016 Feb; 18(1):26. PubMed ID: 26921175
[TBL] [Abstract][Full Text] [Related]
9. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression.
Zhang Z; Qiu N; Yin J; Zhang J; Liu H; Guo W; Liu M; Liu T; Chen D; Luo K; Li H; He Z; Liu J; Zheng G
Theranostics; 2020; 10(10):4290-4307. PubMed ID: 32292495
[No Abstract] [Full Text] [Related]
10. Expression and prognostic role of orphan receptor GPR110 in glioma.
Shi H; Zhang S
Biochem Biophys Res Commun; 2017 Sep; 491(2):349-354. PubMed ID: 28728843
[TBL] [Abstract][Full Text] [Related]
11. YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.
Takeda T; Yamamoto H; Suzawa K; Tomida S; Miyauchi S; Araki K; Nakata K; Miura A; Namba K; Shien K; Soh J; Shien T; Kitamura Y; Sendo T; Toyooka S
Cancer Sci; 2020 Mar; 111(3):849-856. PubMed ID: 31856375
[TBL] [Abstract][Full Text] [Related]
12. NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer.
Jiang L; Ren L; Chen H; Pan J; Zhang Z; Kuang X; Chen X; Bao W; Lin C; Zhou Z; Huang D; Yang J; Huang H; Wang L; Hou N; Song L
Cell Death Dis; 2020 Jul; 11(7):547. PubMed ID: 32683421
[TBL] [Abstract][Full Text] [Related]
13. The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation.
Polycarpou-Schwarz M; Groß M; Mestdagh P; Schott J; Grund SE; Hildenbrand C; Rom J; Aulmann S; Sinn HP; Vandesompele J; Diederichs S
Oncogene; 2018 Aug; 37(34):4750-4768. PubMed ID: 29765154
[TBL] [Abstract][Full Text] [Related]
14. ZC3H15 Correlates with a Poor Prognosis and Tumor Progression in Melanoma.
Li Q; Hou J; Guo C; Zhang Y; Liu L; Hu H; Shi S; Ji Y; Guo L; Shi Y; Liu Y; Cui H
Biomed Res Int; 2021; 2021():8305299. PubMed ID: 34988227
[TBL] [Abstract][Full Text] [Related]
15. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
[TBL] [Abstract][Full Text] [Related]
16. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
17. The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.
Lo PK; Lee JS; Liang X; Sukumar S
Cell Signal; 2016 Oct; 28(10):1502-19. PubMed ID: 27377963
[TBL] [Abstract][Full Text] [Related]
18. Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function.
Lee JW; Huang BX; Kwon H; Rashid MA; Kharebava G; Desai A; Patnaik S; Marugan J; Kim HY
Nat Commun; 2016 Oct; 7():13123. PubMed ID: 27759003
[TBL] [Abstract][Full Text] [Related]
19. ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network.
Qian H; Ji R; Shen C; Wei Y; Sheng C; Ni Q; Pan J; Chi Y; You H; Miao Y; Shi M; Huang X; Shen A
Aging (Albany NY); 2023 Dec; 15(24):14996-15024. PubMed ID: 38126976
[TBL] [Abstract][Full Text] [Related]
20. Prolactin hormone exerts anti-tumorigenic effects in HER-2 overexpressing breast cancer cells through regulation of stemness.
Hachim IY; López-Ozuna VM; Hachim MY; Lebrun JJ; Ali S
Stem Cell Res; 2019 Oct; 40():101538. PubMed ID: 31450192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
